Analyst Price Targets — NGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 7:18 pm | — | Maxim Group | $12.00 | $4.18 | TheFly | NervGen Pharma price target raised to $12 from $10 at Maxim |
Latest News for NGEN
VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial. NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting focus to NVG-291's ability to replicate efficacy in chronic tetraplegia. Objective biomechanical gait analysis showed statistically significant improvements, reinforcing the case for NVG-291's…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NGEN.
U.S. House Trading
No House trades found for NGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.